drugset / Trial / NCT03169764
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with HNSCC who have progressed on or after previous chemotherapy and anti-PD-1/PD-L1 therapy.
Timeline
- Start
- 2017-12
- Primary completion
- 2019-01
- Completion
- 2021-12-28
Outcome
Outcome not reported
Stopped: “Trial not initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 5-Fluorouracil (5-FU) | Small molecule | — | — |
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | ETBX-011 | Vaccine | — | — |
| Subject | ETBX-021 | Vaccine | — | — |
| Subject | ETBX-051 | Vaccine | — | — |
| Subject | ETBX-061 | Vaccine | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | GI-4000 | Vaccine | — | — |
| Subject | GI-6207 | Vaccine | — | — |
| Subject | GI-6301 | Vaccine | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Lovaza | Other / unclassified | — | — |
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | haNK | Cell therapy | — | Intravenous |